Medical Treatment of Vitiligo

Surgical Management of Vitiligo

Volumn , Issue , 2007, Pages 31-38

  Passeron, Thierry ^a   Ortonne, Jean Paul ^a  

^a UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Corticosteroids; Micro phototherapy; Oral PUVA photochemotherapy; Phototherapy; Vitiligo

Indexed keywords

EID: 43749119926     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987568.ch4     Document Type: Chapter

References (45)

1. Kent G, Al'Abadie M. Psychologic effects of vitiligo: a critical incident analysis. J Am Acad Dermatol 1996; 35:895-8.
2. Parsad D, Pandhi R, Dogra S, et al. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol 2003; 148:373-4.
3. Ortonne JP, Passeron T. Melanin pigmentary disorders: treatment update. Dermatol Clin 2005; 23:209-26.
4. Njoo MD, Spuls PI, Bos JD, et al. Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 1998; 134:1532-40.
5. Passeron T. UVB therapy for pigmentary disorders. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, and Ortonne JP (eds.) The Pigmentary System. 2nd ed. New York: Oxford University Press, 2006;1183-7.
6. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141:108-12.
7. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow-up study. N Engl J Med 1997; 336:1041-5.
8. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44:755-61.
9. Garland CF, Garland FC, Gorham ED. Epidemiologic evidence for different roles of ultraviolet A and B radiation in melanoma mortality rates. Ann Epidemiol 2003; 13:395-404.
10. Slaper H, Schothorst AA, van der Leun JC. Risk evaluation of UVB therapy for psoriasis: comparison of calculated risk for UVB therapy and observed risk in PUVA-treated patients. Photodermatology 1986; 3:271-83.
11. Schaffer JV, Bolognia JL. The treatment of hypopigmentation in children. Clin Dermatol 2003; 21:296-310.
12. Grimes PE. Psoralen photochemotherapy for vitiligo. Clin Dermatol 1997; 15:921-6.
13. Koster W, Wiskemann A. [Phototherapy with UV-B in vitiligo]. Z Hautkr 1990;65:1022-4, 1029.
14. Hartmann A, Lurz C, Hamm H, et al. Narrow-band UVB 311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol 2005; 44:736-42.
15. Mofty ME, Zaher H, Esmat S, et al. PUVA and PUVB in vitiligo-Are they equally effective? Photodermatol Photoimmunol Photomed 2001;17:159-63.
16. Ortonne J. Vitiligo and other disorders of hypopigmentation. In: Bolognia J, Jorizzo J and Rapini R (eds) Dermatology, Vol. I. New York: Mosby, 2003;947-73.
17. Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995; 190:223-9.
18. Lotti TM, Menchini G, Andreassi L. UV-B radiation microphototherapy. An elective treatment for segmental vitiligo. J Eur Acad Dermatol Venereol 1999; 13:102-8.
19. Menchini G, Tsoureli-Nikita E, Hercogova J. Narrowband UV-B micro-phototherapy: a new treatment for vitiligo. J Eur Acad Dermatol Venereol 2003; 17:171-7.
20. Leone G, Iacovelli P, Paro Vidolin A, Picardo M. Monochromatic excimer light 308 nm in the treatment of vitiligo: a pilot study. J Eur Acad Dermatol Venereol 2003; 17:531-7.
21. Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205:301-3.
22. Mayoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003; 207:322-3.
23. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47:789-91.
24. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A doubleblind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139:581-5.
25. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15:88-91.
26. Ostovari N, Passeron T, Lacour JPh, Ortonne JP. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UVB exposure in difficult to treat sites. Arch Dermatol 2006; 142:252-3.
27. Westerhof W, Nieuweboer-Krobotova L, Mulder PG, Glazenburg EJ. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999; 135:1061-6.
28. Patel DC, Evans AV, Hawk JL. Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-centre study. Clin Exp Dermatol 2002; 27:641-4.
29. Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology 1998; 197:167-70.
30. Ermis O, Alpsoy E, Cetin L, Yilmaz E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol 2001; 145:472-5.
31. Baysal V, Yildirim M, Erel A, Kesici D. Is the combination of calcipotriol and PUVA effective in vitiligo? J Eur Acad Dermatol Venereol 2003;17:299-302.
32. Kullavanijaya P, Lim HW. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo. Photodermatol Photoimmunol Photomed 2004; 20:248-51.
33. Ada S, Sahin S, Boztepe G, Karaduman A, Kolemen F. No additional effect of topical calcipotriol on narrowband UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed 2005; 21:79-83.
34. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140:1065-9.
35. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30:130-5.
36. Castanedo-Cazares JP, Lepe V, Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow-band. Photodermatol Photoimmunol Photomed 2003; 19:35-6.
37. Tanghetti EA, Gillis PR. Clinical evaluation of B clear and protopic treatment for vitiligo. Laser Surg Med 2003;32:37.
38. Parsad D, Pandhi R, Dogra S, Kumar B. Topical prostaglandin analog (PGE2) in vitiligo-a preliminary study. Int J Dermatol 2002; 41:942-5.
39. Mosher DB, Parrish JA, Fitzpatrick TB. Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol 1977; 97:669-79.
40. Silvan M. The psychological aspects of vitiligo. Cutis 2004; 73:163-7.
41. Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol 2000; 42:760-9.
42. Ongenae K, Dierckxsens L, Brochez L, van Geel N, Naeyaert JM. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology 2005; 210:279-85.
43. Levy SB. Tanning preparations. Dermatol Clin 2000; 18:591-6.
44. Suga Y, Ikejima A, Matsuba S, Ogawa H. Medical pearl: DHA application for camouflaging segmental vitiligo and piebald lesions. J Am Acad Dermatol 2002; 47:436-8.
45. Ongenae K, Van Geel N, De Schepper S, et al. Management of vitiligo patients and attitude of dermatologists towards vitiligo. Eur J Dermatol 2004; 14:177-81.